Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Invested Capital (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Invested Capital data on record, last reported at $523.9 million in Q3 2025.

  • For Q3 2025, Invested Capital fell 28.04% year-over-year to $523.9 million; the TTM value through Sep 2025 reached $523.9 million, down 28.04%, while the annual FY2024 figure was $692.2 million, 49.76% up from the prior year.
  • Invested Capital reached $523.9 million in Q3 2025 per VRDN's latest filing, down from $536.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $728.0 million in Q3 2024 and bottomed at $98.9 million in Q2 2021.
  • Average Invested Capital over 5 years is $390.7 million, with a median of $399.7 million recorded in 2022.
  • Peak YoY movement for Invested Capital: skyrocketed 872.3% in 2021, then fell 28.04% in 2025.
  • A 5-year view of Invested Capital shows it stood at $187.7 million in 2021, then skyrocketed by 112.93% to $399.7 million in 2022, then rose by 15.64% to $462.2 million in 2023, then skyrocketed by 49.76% to $692.2 million in 2024, then fell by 24.32% to $523.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $523.9 million in Q3 2025, $536.0 million in Q2 2025, and $625.2 million in Q1 2025.